Orlewska E - Search Results

1

Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.

Orlewska E, Mierzejewski P. Orlewska E, et al. Value Health. 2004 Jan-Feb;7(1):1-10. doi: 10.1111/j.1524-4733.2004.71257.x. Value Health. 2004. PMID: 14720125 Free article.

2

The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.

Orlewska E. Orlewska E. Value Health. 2002 Sep-Oct;5(5):405-21. doi: 10.1046/J.1524-4733.2002.55147.x. Value Health. 2002. PMID: 12201858 Free article.

3

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.

Orlewska E, Budaj A, Tereszkowski-Kaminski D. Orlewska E, et al. Pharmacoeconomics. 2003;21(10):737-48. doi: 10.2165/00019053-200321100-00005. Pharmacoeconomics. 2003. PMID: 12828495

4

Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines.

Orlewska E, Mierzejewski P. Orlewska E, et al. Eur J Health Econ. 2003 Nov;4(4):296-303. doi: 10.1007/s10198-003-0185-2. Eur J Health Econ. 2003. PMID: 15609200

5

A prospective study of the financial costs of multiple sclerosis at different stages of the disease.

Orlewska E, Mierzejewski P, Zaborski J, Kruszewska J, Wicha W, Fryze W, Drozdowski W, Skibicka I, Mirowska-Guzel D, Czlonkowski A, Czlonkowska A. Orlewska E, et al. Eur J Neurol. 2005 Jan;12(1):31-9. doi: 10.1111/j.1468-1331.2004.00950.x. Eur J Neurol. 2005. PMID: 15613144

6

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Mauskopf JA, et al. Among authors: orlewska e. Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x. Value Health. 2007. PMID: 17888098 Free article.

7

Budget-impact analyses: a critical review of published studies.

Orlewska E, Gulácsi L. Orlewska E, et al. Pharmacoeconomics. 2009;27(10):807-27. doi: 10.2165/11313770-000000000-00000. Pharmacoeconomics. 2009. PMID: 19803537 Review.

8

Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY. Sullivan SD, et al. Among authors: orlewska e. Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13. Value Health. 2014. PMID: 24438712 Free article.

9

Economic aspects in medical decision-making.

Orlewska E. Orlewska E. Transplant Proc. 2003 May;35(3):1227-9. doi: 10.1016/s0041-1345(03)00200-8. Transplant Proc. 2003. PMID: 12947913 No abstract available.

10

Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.

Redekop WK, Orlewska E, Maciejewski P, Rutten FF, Niessen LW. Redekop WK, et al. Among authors: orlewska e. Pharmacoeconomics. 2008;26(10):861-77. doi: 10.2165/00019053-200826100-00006. Pharmacoeconomics. 2008. PMID: 18793033

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters